SCOTTSDALE, Ariz., April 11, 2018 -- Clinical Laserthermia Systems Americas, Inc. (CLS) a subsidiary of CLS AB in Lund, Sweden, today announced it will be exhibiting its TRANBERG® Thermal Therapy System, mobile laser, and single-use products at the 23rd Annual Southwest Prostate Cancer Symposium being held at the Fairmont Scottsdale Princess, Arizona, April 12-15, 2018.
The TRANBERG Thermal Therapy System is designed to reduce morbidity and improve clinical outcomes within interventional oncology and urology. The system is currently in use at hospitals in the U.S. for MRI-guided focal laser ablation treatment, and included in clinical studies in Canada and Europe.
The 23rd Annual Southwest Prostate Cancer Symposium brings together world-renowned experts in the management of prostate cancer and will provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.
CLS High Precision Thermal Therapy System
The TRANBERG® |Thermal Therapy System has been developed for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, external tissue temperature probe sensors, and procedure specific accessories.
Laser Applicator Non-cooled
The applicator portfolio includes 3m and 12m non-cooled 16 Gauge laser applicators allowing for almost any type of image guidance, including MR. With CLS’ unique diffusing fiber technology, heat distribution in tissue is optimized and the need for external cooling is eliminated. Features also aimed at improving workflow and shortening procedure time.
About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System including its specially-designed sterile disposable products for safe, gentle and effective treatment of soft tissue such as cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed on Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se.
The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).
Media Contact TopSpin Communications Joe Waldygo P: 480-363-8774 E: [email protected] Company Contact CLS Americas, Inc. Alan Weinberg, General Manager P: (508) 620-4521 E: [email protected]


Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
How Marco Pharma International Preserves German Homeopathic Traditions in America
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 



